In a pooled analysis of tumor tissue samples from three KEYNOTE clinical trials assessing pembrolizumab efficacy and safety in patients with advanced NSCLC, PD-L1 expression at TC ≥50% was found in 28% of tumors [41]. Here, CD274 is linked to non-small cell lung carcinoma.